Booth Bruce sold $3.3M of KYMR (indirect holdings)
Booth Bruce sold 31,798 indirectly-held shares of Kymera Therapeutics, Inc. (KYMR) at an average of $103.75 ($103.42–$104.38, $3.30M total) across 4 trades on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest actionable element is the disclosed sale size ($3.3M), execution date, and the fact it was conducted under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor KYMR for any follow-on insider activity or unusual volume, but this single 10b5-1 sale is unlikely to drive a major repricing by itself.
What to watch
The filing does not disclose reasons for the sale; without concurrent operational/regulatory/clinical updates, traders should avoid extrapolating fundamentals from this alone.
Background
The article is an SEC Form 4 insider transaction: director Booth Bruce sold KYMR shares in multiple trades on 2026-06-22.
Ticker impact
Kymera Therapeutics director Booth Bruce sold $3.3M of KYMR via an open-market sale under a pre-arranged 10b5-1 plan on 2026-06-22.
Likely limited, short-lived sentiment impact; any move should be small versus broader tape unless paired with other catalysts.
Form 4 provides a primary datapoint (sale size and timing) but the transaction is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight for directional fundamental change.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
None indicated; US-listed biotech insider sale only.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may be routine liquidity rather than a bearish signal.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure (KYMR).
- insiderBooth Bruce
Director who executed the open-market sale under a 10b5-1 plan.
